Abstract
Development of SAR in an N-acyl-N′-arylpiperazine series of negative allosteric modulators of mGlu1 using a functional cell-based assay is described in this Letter. Characterization of selected compounds in protein binding assays was used to aid in selecting VU0469650 for further profiling in ancillary pharmacology assays and pharmacokinetic studies. VU0469650 demonstrated an excellent selectivity profile and good exposure in both plasma and brain samples following intraperitoneal dosing in rats.
Original language | English |
---|---|
Pages (from-to) | 3713-3718 |
Number of pages | 6 |
Journal | Bioorganic and Medicinal Chemistry Letters |
Volume | 23 |
Issue number | 13 |
DOIs | |
State | Published - 1 Jul 2013 |
Keywords
- Allosteric modulator
- CNS
- GPCR mGlu
- Glutamate
- Piperazine